The broking firm has maintained its ‘outperform’ rating on Coal India citing increase in costs will offset some of the price hikes. It also raised its target price to Rs 425 from Rs 420 earlier.

"We factor in the 4.8 percent announced price increase, and raise our volume estimates by 5 percent growth in FY14/15 but increasing costs moderate the impact on EPS. Our FY14 and FY15 expected earnings per shares also moved up by 7 percent and 1 percent respectively. Fair value moves to Rs425. Maintain OUTPERFORM," said the Credit Suisse note.

Sun Pharma: OUTPERFORM, TP Rs 1120

Credit Suisse has raised its target price on Sun Pharma to Rs 1120 from Rs 900 as the company continues to beat broking firm’s earning estimates and remains the best play for US generic story.

“We increase our target price to Rs1,120 (from Rs900) as we increase FY14/15 EPS by 16/14 percent due to incorporation of URL. Key short-term event is outcome of the Protonix litigation which is expected next month,” said the CS note.

Colgate Palmolive: UNDERPERFORM, TP: Rs 1275

CS has maintained its 'underperform' rating on Colgate Palmolive citing the impending launch of P&G’s Oral-B toothpaste in India in June. However, the firm raised its target price to Rs 1275 from Rs 1232 earlier.

"The key overhang on the stock would be the impending launch of P&G’s Oral-B toothpaste in India in June. Management stated that it intends to maintain share of voice and hence could increase ad spends. We cut our estimates by 3 percent to build in higher expenses and maintain UNDERPERFORM. Target price increases to Rs 1,275 as we roll forward to Mar-15," said the brokerage house note.